Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.528
-0.008 (-1.57%)
At close: Feb 27, 2026, 4:00 PM EST
0.540
+0.012 (2.21%)
After-hours: Feb 27, 2026, 7:59 PM EST
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $19.07M in the quarter ending September 30, 2025, with 742.51% growth. This brings the company's revenue in the last twelve months to $31.80M, up 588.40% year-over-year. In the year 2024, Xilio Therapeutics had annual revenue of $6.34M.
Revenue (ttm)
$31.80M
Revenue Growth
+588.40%
P/S Ratio
1.22
Revenue / Employee
$496,938
Employees
64
Market Cap
38.81M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 151.93M |
| NovaBay Pharmaceuticals | 10.30M |
| CervoMed | 6.16M |
| Rallybio | 674.00K |
| Actinium Pharmaceuticals | 90.00K |
XLO News
- 17 days ago - Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript - Seeking Alpha
- 4 months ago - Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewsWire